Previously the Executive Director of MAPS (Multidisciplinary Association for Psychedelic Studies) Canada for 10 years, Mark is an adjunct professor at the University of British Columbia School of Population and Public Health, and has published on the issue of drug control policy and psychedelics. Mark also worked in the addictions field in counseling, supervisory and management positions for 28 years.
Mark has provided public education on drugs and drug policy for over 30 years. Mark works with the Health Officers Council of British Columbia on their position papers on the issue of a regulated market for all currently illegal drugs. Has presented in conferences and training events in many countries. Awarded the Queen’s Diamond Jubilee Medal for drug policy reform work in 2013. Mark is the Director of Clinical Research for Psygen.
Clearmind Medicine Background:
Clearmind Medicine (CSE: CMND, FSE: CWY) develops novel psychedelic medicines to solve widespread, yet under-served, health problems. With a strong medical management team and IP-protection, we can better the lives of millions.
With a clear focus on alcohol abuse and binge drinking, Clearmind’s first drug candidate addresses very common (and costly) afflictions which to date, have limited solutions.
Listen to Mark & Mark here:
